NEW YORK, Dec. 27 - Valentis has pocketed $13.8 million in an underwritten public offering of its common stock, the company said on Thursday.
Valentis offered the 6,130,007 shares, and Wells Fargo Van Kasper acted as underwriter.
In October, Burlingame, Calif.-based Valentis gave Pfizer a non-exclusive, research-only license to its GeneSwitch gene-regulation technology.
The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures.